艾美疫苗(6660.HK):三大重磅單品疫苗今年申報上市,公司有望迎來絕地反擊
艾美疫苗(6660.HK)近日發佈多個公吿,13價肺炎結合疫苗已提交上市註冊預申請。13價肺炎結合疫苗、無血清迭代狂犬疫苗、23價肺炎多糖疫苗等三款重磅迭代升級疫苗正在開展申報上市的各項準備工作,預計2024年內完成申報上市。該公司已佈局完畢迭代升級的肺炎疫苗、 狂犬病疫苗系列產品。其中,20價肺炎結合疫苗已提交臨牀試驗預申請,全球同步首研的24價肺炎結合疫苗已完成臨牀前研究工作;新型工藝人二倍體狂犬疫苗預計2024年上半年提交臨牀試驗預申請,全球首研的mRNA狂犬疫苗是國內受理的第一款非新冠疫苗產品。此外,四價結合流腦疫苗2期臨牀試驗已啟動,生產車間已建成。吸附破傷風疫苗已提交臨牀試驗預申請,公司吸附無細胞百白破-HIB聯合疫苗臨牀試驗申請年內陸續啟動。據2023年業績預吿,在銷售收入與2022年度基本持平的前提下,鑑於新冠疫情變化,公司大幅計提無形資產及商譽減值,以及5個主要核心產品均處於三期臨牀,使得2023年度研發費用大幅增加,業績預虧。預計隨着公司多個重磅新產品集中上市,艾美有望迎來絕地反擊。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.